Related Experiment Video

Updated: May 15, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Vemurafenib: a guide to its use in unresectable or metastatic melanoma

Gillian M Keating1, Katherine A Lyseng-Williamson

  • 1Adis, 41 Centorian Drive Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. der@adis.com

American Journal of Clinical Dermatology
|January 19, 2013
PubMed

Insights

Oral vemurafenib (BRAF inhibitor) significantly improved survival outcomes for melanoma patients compared to dacarbazine. This targeted therapy was generally well-tolerated, with skin-related side effects being most common.

Area of Science:

  • Oncology
  • Pharmacology
  • Dermatology

Background:

  • Melanoma is a significant cause of cancer mortality.
  • BRAF V600E mutations are common drivers in melanoma.
  • Targeted therapies offer new treatment avenues for melanoma.

Purpose of the Study:

  • To evaluate the efficacy and safety of oral vemurafenib in BRAF V600E-positive melanoma.
  • To compare vemurafenib with intravenous dacarbazine in a specific melanoma patient population.

Main Methods:

  • A comparative study involving patients with unresectable, previously untreated, BRAF V600E-positive, stage IIIC or IV melanoma.
  • Treatment arms included oral vemurafenib and intravenous dacarbazine.
  • Overall survival and progression-free survival were key endpoints.

Main Results:

  • Vemurafenib demonstrated significant improvements in overall survival compared to dacarbazine.
  • Progression-free survival was also significantly enhanced with vemurafenib treatment.
  • The most frequent adverse events were cutaneous, indicating good general tolerability.

Conclusions:

  • Oral vemurafenib is an effective targeted therapy for BRAF V600E-positive metastatic melanoma.
  • Vemurafenib offers survival benefits over traditional chemotherapy in this patient group.
  • Monitoring for cutaneous adverse events is important during vemurafenib treatment.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...